Patents by Inventor Jonathan S. Stamler

Jonathan S. Stamler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220251102
    Abstract: An aldoketo reductase inhibitor includes a xanthene analogue.
    Type: Application
    Filed: September 23, 2020
    Publication date: August 11, 2022
    Inventors: WILLIAM GREENLEE, JONATHAN S. STAMLER
  • Publication number: 20220184143
    Abstract: A method of treating a disorder associated gasotransmitter signaling in a subject in need thereof includes modulating the microbiota of the subject to modulate microbiota gasotransmitter production and modification of the subject's proteome to treat the disorder in the subject.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 16, 2022
    Inventor: Jonathan S. Stamler
  • Publication number: 20220117909
    Abstract: A method of treating coronavirus infection, post-acute sequelae of coronavirus infection, and viral mediated respiratory distress in a subject in need thereof includes administering to the subject a therapeutically effective amount of agent that promotes, increases, and/or induces hemoglobin nitrosylation within red blood cells (RBCs) and GSNO levels in the lung or airways of the subject.
    Type: Application
    Filed: December 27, 2021
    Publication date: April 21, 2022
    Inventor: Jonathan S. Stamler
  • Publication number: 20210347744
    Abstract: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.
    Type: Application
    Filed: September 23, 2019
    Publication date: November 11, 2021
    Applicant: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Jonathan S. Stamler, William Greenlee
  • Publication number: 20210267943
    Abstract: A method for preventing or treating a tissue injury and/or promoting tissue repair in a subject in need thereof, includes administering to the subject a therapeutically effective amount of an ADH inhibitor, AKR inhibitor, SCoR inhibitor, and/or PKM2 inhibitor.
    Type: Application
    Filed: June 25, 2019
    Publication date: September 2, 2021
    Inventor: Jonathan S. Stamler
  • Publication number: 20200268717
    Abstract: A method of lowering cholesterol and/or PCSK9 levels in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to reduce serum cholesterol and/or PCSK9 levels.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 27, 2020
    Inventor: Jonathan S. Stamler
  • Publication number: 20200164122
    Abstract: Devices and methods are provided herein for exchange between a first agent and a second agent. The device includes a first chamber having a first inlet and a first outlet with a first flow passageway extending between the first inlet and the first outlet for flowing a first agent through the first chamber. The device also includes a second chamber having a second inlet and a second outlet with a second flow passageway extending between the second inlet and the second outlet for flowing a second agent through the second chamber and a membrane positioned between the first flow passageway and the second flow passageway to allow exchange through the membrane of the first agent with the second agent. Methods of nitrosylating blood and methods of manufacturing the device are also provided.
    Type: Application
    Filed: June 7, 2018
    Publication date: May 28, 2020
    Applicant: Case Western Reserve University
    Inventors: Harihara BASKARAN, Jonathan S. STAMLER, James D. REYNOLDS, Jim A. BERILLA
  • Publication number: 20200114110
    Abstract: Devices for delivering a controlled concentration of an agent are provided. The device includes a reservoir for the agent and a flow control portion operably connected to the reservoir. The device also includes a valve for releasing the agent from the flow control portion and a pump for flowing air to mix with the agent released by the valve and for flowing the agent and air mixture out of the device. Methods of delivering a vaporized agent to a subject are also provided. The methods include storing a liquid agent in a reservoir of a device and flowing the agent into a flow control chamber to change the agent to a gas. The methods also include mixing the agent in gas form with air and flowing the agent and air mixture out of the device to be delivered to a subject.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 16, 2020
    Applicant: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Jonathan S. STAMLER
  • Publication number: 20190183861
    Abstract: A method of treating cardiovascular disorders and diseases in a subject in need therof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 20, 2019
    Inventor: Jonathan S. Stamler
  • Publication number: 20180292346
    Abstract: A gaseous nitric oxide (NO) sensor having a working electrode configured such to induce NO molecules proximate the working electrode to undergo an electrochemical oxidation reaction. The electrochemical oxidation reaction transfers electrons from the NO molecules to the working electrode, creating a measurable current corresponding to the NO concentration within the fluid sample. An external membrane can be deposited onto the working electrode to separate the fluid sample from the working electrode. The external membrane can comprise an ionomer selectively permitting diffusion of NO molecules through the external membrane from the fluid sample to the working electrode. In an example, the fluid sample can be heated to a predetermined temperature to facilitate dissociation of NO from its hemoglobin bonded forms proximate the external membrane.
    Type: Application
    Filed: April 10, 2018
    Publication date: October 11, 2018
    Inventors: Michael E. Collison, Amanda Marie Franey, Gregory Scott Buell, Lyna Anderson, Jonathan S. Stamler
  • Patent number: 9651530
    Abstract: An exemplary apparatus for measuring nitric oxide in a fluid includes a sample injection port; a pump and reservoir; a valve; a measurement chamber; an electromagnetic radiation source; controls and user interface; and a cartridge. The cartridge includes a sample chamber a mix chamber; a sample degassing chamber; and a planar reaction chamber. The cartridge preferably is single-use and disposable. Furthermore, additional inventive aspects and features are disclosed related to measuring nitric oxide in a fluid.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 16, 2017
    Assignee: LifeHealth, LLC
    Inventors: Scott Everett Blomberg, Mark Louis Peterson, Amanda Marie Franey, Jonathan S. Stamler
  • Patent number: 9562913
    Abstract: Amount of combined nitric oxide or nitric oxide presented as iron nitrosyls in a blood sample is determined by directing a low power electromagnetic radiation beam at a blood sample to liberate nitric oxide gas, dissolving the liberated nitric oxide gas and electrochemically detecting amount of dissolved nitric oxide gas.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 7, 2017
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Michael Angelo
  • Publication number: 20160106773
    Abstract: Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx/Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Inventors: Jonathan S. STAMLER, Moran BENHAR
  • Patent number: 9063160
    Abstract: Amount of combined nitric oxide or nitric oxide present as iron nitrosyls in a blood sample is determined by directing a low power electromagnetic radiation beam at a blood sample to liberate nitric oxide gas, dissolving the liberated nitric oxide gas and electrochemically detecting amount of dissolved nitric oxide gas.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: June 23, 2015
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Michael Angelo
  • Patent number: 9056080
    Abstract: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 16, 2015
    Assignee: Duke University
    Inventors: Mark W. Dewhirst, Jonathan S. Stamler, Timothy J. McMahon, Pierre D. Sonveaux
  • Publication number: 20140332416
    Abstract: Amount of combined nitric oxide or nitric oxide presented as iron nitrosyls in a blood sample is determined by directing a low power electromagnetic radiation beam at a blood sample to liberate nitric oxide gas, dissolving the liberated nitric oxide gas and electrochemically detecting amount of dissolved nitric oxide gas.
    Type: Application
    Filed: May 22, 2014
    Publication date: November 13, 2014
    Applicant: Duke University
    Inventors: Jonathan S. Stamler, Michael Angelo
  • Patent number: 8871506
    Abstract: The present invention relates to methods of treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation; treatment of cardiac and blood disorders; treatment of patient in need of improved oxygenation, blood flow of and/or thinning of blood and method of screening drugs that increase level of nitrosoglutathione in airway lining fluid.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: October 28, 2014
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Eric J. Toone, Andrew J. Gow
  • Publication number: 20140314881
    Abstract: A body part is preserved using nitric oxide and/or a nitric oxide donor that does not directly release nitric oxide or a red blood cell nitrosylating agent, preferably ethyl nitrite to facilitate oxygen supply. A subject at risk for developing high altitude illness is administered a red blood nitrosylating agent in gaseous form that does not directly release nitric oxide, preferably ethyl nitrite.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 23, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: James D. Reynolds, Jonathan S. Stamler
  • Patent number: 8853168
    Abstract: Avicins and other thioesterification agents are used to modify cysteine groups of signaling proteins in order to modify their activity. Pathologies associated with signaling proteins which are regulatable through this method are treated using these thioesterification agents. These pathologies include those involving proteins which modulate physiologic redox status of organisms including arthersclerosis, cancer, bacterial infection, inflammation, and neurological disorders.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: October 7, 2014
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Jordan Gutterman
  • Patent number: 8815297
    Abstract: This present invention relates to methods, compositions, and kits useful for treating a patient having or at risk for developing a disorder associated with decreased expression of ?2 adrenergic receptors or need for increased 132 adrenergic receptor activity.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: August 26, 2014
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Liang Xie